Kalciumfolinat Stada (Calcium Folinate)

Calcium folinate bypasses the inhibition of dihydrofolate reductase caused by antifolate drugs, directly supplying tetrahydrofolate cofactors needed for DNA synthesis and cellular metabolism, thereby protecting normal cells while allowing chemotherapy to target malignant cells.

The appropriate dose of Kalciumfolinat Stada is determined by the prescribing clinician based on the specific indication, patient weight, renal function, and the chemotherapy protocol being used. Dosage instructions are provided on the prescription label.

Safety in pregnancy and lactation has not been definitively established. The prescriber should evaluate the potential benefits against possible risks before administering calcium folinate to pregnant or nursing women.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Calcium folinate is a reduced‑form folate that acts more rapidly than oral folic acid supplements and provides a direct source of tetrahydrofolate. Compared with leucovorin, it offers similar rescue efficacy but may differ in formulation and stability, influencing storage and handling requirements.

Kalciumfolinat Stada should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze the product, and avoid shaking the vial to maintain solution integrity.

The product is administered by a healthcare professional via intramuscular or intravenous injection, according to the prescriber’s instructions and the clinical protocol being followed.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, acute renal impairment, significant blood‑cell count reductions (neutropenia, thrombocytopenia), and rare pulmonary toxicity. Immediate medical attention is required if these events occur.

Patients with known hypersensitivity to calcium folinate or any excipients, those receiving high‑dose folate antagonists without medical supervision, and individuals with severe renal or hepatic impairment should avoid using this product unless specifically directed by a qualified clinician.